orteronel + leuprorelin

TAK-700 + LHRH agonist is a combination drug regimen consisting of orteronel (TAK-700) and a luteinizing hormone-releasing hormone (LHRH) agonist, specifically leuprorelin acetate. Orteronel is an oral, selective nonsteroidal small molecule inhibitor of the enzyme CYP17A1, specifically targeting its 17,20-lyase activity to block androgen biosynthesis in the testes, adrenal glands, and prostate tumor tissue. The LHRH agonist component, leuprorelin acetate, suppresses gonadal androgen production by downregulating the hypothalamic-pituitary-gonadal axis. Together, the combination is designed to achieve comprehensive androgen deprivation. This regimen has been investigated as a neoadjuvant therapy for patients with intermediate and high-risk clinically localized prostate cancer prior to radical prostatectomy. While orteronel was originally developed by Millennium Pharmaceuticals (a Takeda subsidiary), its global development for prostate cancer was largely discontinued following Phase 3 results that did not meet primary endpoints for overall survival in metastatic castration-resistant prostate cancer.

Other names

orteronel + leuprorelin acetateTAK-700 + LHRH agonistTAK-700 + leuprorelin